Assess whether pediatric studies are necessary or waivable (2ed21f)

Situation

A mid-size sponsor after a complete response letter cannot treat a literature paper the 505(b)(2) package leans on getting retracted as color commentary on RWE protocol that may not meet regulator expectations. CMC change-control owner must close pediatric studies are necessary from that extract under Pharma & Life Sciences / Pharmacovigilance.

Decision

CMC change-control owner in a mid-size sponsor after a complete response letter must choose Pediatric studies are necessary / Waivable using RWE protocol that may not meet regulator expectations after a literature paper the 505(b)(2) package leans on getting retracted.

Hypotheses to test

• CMC change-control owner can defend Pediatric studies are necessary from RWE protocol that may not meet regulator expectations after a literature paper the 505(b)(2) package leans on getting retracted in a Pharma & Life Sciences challenge.
• CMC change-control owner cannot defend Pediatric studies are necessary from RWE protocol that may not meet regulator expectations; Waivable is what the extract actually supports after a literature paper the 505(b)(2) package leans on getting retracted.
• A literature paper the 505(b)(2) package leans on getting retracted never reached the population in RWE protocol that may not meet regulator expectations — reopen intake, do not close pediatric studies are necessary.
• Two facts in RWE protocol that may not meet regulator expectations after a literature paper the 505(b)(2) package leans on getting retracted conflict for CMC change-control owner; hold this Pharmacovigilance file.

Analysis required

• Check whether RWE protocol that may not meet regulator expectations supports the labeled claim CMC change-control owner would keep.
• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after a literature paper the 505(b)(2) package leans on getting retracted.
• For this Pharma & Life Sciences Pharmacovigilance file, read RWE protocol that may not meet regulator expectations against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move pediatric studies are necessary for CMC change-control owner.

Recommendation